$326.260
-11.974 (-3.67%)收盘时
NTRA 资讯
NTRA 事件
Natera Collaborates with Angiex on Signatera Testing
Natera announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates, or ND-ADCs. Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. The trial is currently enrolling patients with unresectable, locally advanced or metastatic solid tumors. The collaboration will include longitudinal Signatera testing for circulating tumor DNA to explore its value for treatment response monitoring during AGX101 treatment. Natera's Signatera test provides a personalized measure of ctDNA that may complement radiologic assessment.
Natera Collaborates with Kupando on KUP-101 Clinical Trial
Natera announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics. Under the agreement, Natera's Latitude tissue-free assay for molecular residual disease detection will be used in Kupando's clinical trial of its lead immunotherapy candidate, KUP-101. The trial will assess serial circulating tumor DNA dynamics as part of treatment response monitoring. Patients with advanced tumors across multiple skin cancers will be treated with KUP-101 and Latitude MRD testing will be performed at multiple timepoints. Following the successful dosing of the first patient, Kupando's safety committee has approved the ongoing enrollment of further patients across the activated clinical sites, including leading oncology centers in Germany. KUP-101 is designed to activate the innate immune system and induce trained immunity. It has potential as a tissue-agnostic treatment across multiple solid tumor types, both as a standalone therapy and in combination with other agents. To evaluate molecular response in this setting, the Latitude test is well suited to assess treatment response in the trial.
Stock Futures Mixed as Doximity Soars 83.93%
Stock futures were mixed following a mostly lower regular session as investors continue to digest another round of corporate earnings and await news out of the Middle East.Economic data remains a central focus ahead of Friday's July employment report. Markets remain divided over the Federal Reserve's next policy move, with incoming employment data expected to play an important role in shaping expectations for interest rates over the coming months.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Doximityup 83.93%Atlassianup 32.1%Figsup 24.6%QuinStreetup 23%Cloudflareup 16.9%Twilioup 16.7%Nateraup 15.3%Akamaiup 13%Airbnbup 10.3%Instacartup 9%ALSO HIGHER -DoubleVerifyup 13.2% after Nielsen agreed to acquire the company in an all-cash transaction valued at roughly $2.15BDOWN AFTER EARNINGS -Trade Deskdown 24.5%QuidelOrthodown 21.8%Xponential Fitnessdown 12.9%Cable Onedown 9.5%Maravai Lifesciencesdown 8.8%ResMeddown 5.9%10x Genomicsdown 4.7%Dropboxdown 4.1%Post Holdingsdown 3%
Natera Reports Q2 Revenue of $752.8M, Exceeding Expectations
Reports Q2 revenue $752.8M, consensus $661.29M. "We had an exceptional quarter helping patients, with over one million tests processed for the second consecutive quarter and record growth in oncology volumes," said Steve Chapman, chief executive officer of Natera. "We also reached several landmark milestones in the last few months: Signatera achieved three significant regulatory approvals, Medicare coverage expanded for Prospera, and we launched a major enhancement to our PanoramaT NIPT."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。